[go: up one dir, main page]

WO2009075678A1 - Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity - Google Patents

Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity Download PDF

Info

Publication number
WO2009075678A1
WO2009075678A1 PCT/US2007/087145 US2007087145W WO2009075678A1 WO 2009075678 A1 WO2009075678 A1 WO 2009075678A1 US 2007087145 W US2007087145 W US 2007087145W WO 2009075678 A1 WO2009075678 A1 WO 2009075678A1
Authority
WO
WIPO (PCT)
Prior art keywords
sec
peak
area
antiperspirant active
aluminum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/087145
Other languages
French (fr)
Inventor
Long Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Priority to PCT/US2007/087145 priority Critical patent/WO2009075678A1/en
Priority to US11/917,863 priority patent/US20100202993A1/en
Priority to ARP080105388A priority patent/AR069657A1/en
Priority to CL2008003684A priority patent/CL2008003684A1/en
Priority to EP14155272.9A priority patent/EP2740465A3/en
Priority to PCT/US2008/086556 priority patent/WO2009076591A1/en
Priority to CN200880120390.9A priority patent/CN101896156B/en
Priority to MX2010006370A priority patent/MX2010006370A/en
Priority to CA2799270A priority patent/CA2799270C/en
Priority to US12/446,045 priority patent/US8257689B2/en
Priority to RU2010128580/15A priority patent/RU2440092C1/en
Priority to AU2008335029A priority patent/AU2008335029B2/en
Priority to ES08859061.7T priority patent/ES2584256T3/en
Priority to EP14155256.2A priority patent/EP2810638B1/en
Priority to EP08859061.7A priority patent/EP2229136B1/en
Priority to CA2706142A priority patent/CA2706142C/en
Priority to CN201210413932.XA priority patent/CN103083195B9/en
Priority to CN201410003540.5A priority patent/CN103690384B/en
Priority to CN201210413190.0A priority patent/CN102920610B/en
Priority to BRPI0820139A priority patent/BRPI0820139B1/en
Priority to EP14155260.4A priority patent/EP2740464B1/en
Publication of WO2009075678A1 publication Critical patent/WO2009075678A1/en
Priority to ZA2010/03774A priority patent/ZA201003774B/en
Anticipated expiration legal-status Critical
Priority to CO10074509A priority patent/CO6290622A2/en
Priority to US13/565,370 priority patent/US8562956B2/en
Priority to ZA2012/06408A priority patent/ZA201206408B/en
Priority to US14/030,492 priority patent/US8795641B2/en
Priority to US14/306,182 priority patent/US9427386B2/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26Aluminium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/28Zirconium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • A61K8/416Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00Anti-perspirants or body deodorants

Definitions

  • Antiperspirant salts such as aluminum chlorohydrex (also called aluminum chlorohydrex polymeric salts and abbreviated here as “ACH”) and aluminum zirconium glycine salts (abbreviated here as “ZAG”, “ZAG complexes” or “AZG”), are known to contain a variety of polymeric and oligomeric species with molecular weights (MW) of 100- 500,000. It has been clinically shown that, in general, the smaller the species, the higher the efficacy for reducing sweat.
  • MW molecular weights
  • Peak 1 is the larger Zr species (greater than 60 Angstroms). Peaks 2 and 3 are larger aluminum species. Peak 4 is smaller aluminum species (aluminum oligomers, or small aluminum cluster) and has been correlated with enhanced efficacy for both Al and Al/Zr salts. Peak 5, 6 is the smallest aluminum species.
  • Various analytical approaches for characterizing the peaks of ACH and various types of ZAG actives are found in "Antiperspirant Actives-Enhanced Efficacy Aluminum-Zirconium-Glycine (AZG) Salts" by Dr. Allan H. Rosenberg (Cosmetics and Toiletries Worldwide, Fondots, D. C. ed., Hartfordshire. UK: Aston Publishing Group, 1993, pages 252. 254-256).
  • the present invention provides for an antiperspirant active composition
  • an antiperspirant active composition comprising an aluminum salt having an aluminum to chloride molar ratio of about 0.3: 1 to about 3: 1, exhibiting a SEC chromatogram having a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution, and optionally including zirconium.
  • the present invention also provides for a method of making an antiperspirant active composition that exhibits a SEC chromatogram having a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution comprising:
  • an aqueous solution containing a zirconium compound to the pH adjusted aluminum salt solution to thereby obtain an aluminum-zirconium salt solution having a molar ratio of aluminum to zirconium of about 5: 1 to about 10:1.
  • Figure 1 illustrates an SEC chromatogram of a prior art antiperspirant active composition.
  • Figure 2 illustrates an SEC chromatogram having exclusive peaks 4 and 5 for an inventive product.
  • Example 1 of the present invention.
  • Figure 3 illustrates an SEC chromatogram having exclusive peak 4 for an inventive product.
  • Example 2 of the present invention.
  • Figure 4 illustrates an SEC chromatogram having exclusive peaks 4 and 5 for an inventive product.
  • Figure 5 illustrates an SEC chromatogram having exclusive peaks 4 and 5 for an inventive product, Example 4, of the present invention.
  • Figure 6 illustrates an SEC chromatogram having exclusive peak 4 for an inventive product.
  • Example 5 of the present invention.
  • Figure 7 illustrates an SEC chromatogram having exclusive peaks 4 and 5 for an inventive product, Example 6, of the present invention.
  • ranges are used as a shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range.
  • the present invention is directed to an antiperspirant active composition having a high SEC peak 4 in aqueous solution.
  • the composition is obtained by a stepwise procedure to neutralize aluminum chloride in a solution (optionally buffered) using inorganic bases.
  • the antiperspirant active compositions obtained by this stepwise procedure include aluminum salts having an aluminum to chloride molar ratio of about 0.3:1 to about 3:1.
  • the aluminum salt has a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution.
  • the composition may optionally include zirconium.
  • a buffer can be included.
  • Buffers that can be used can be chosen from amino acids, glycine, and betaine.
  • the buffer to aluminum molar ratio in certain embodiments can be about 0.1 :1 to about 3:1. In another embodiment, the buffer to aluminum molar ratio is about 0.5:1 to about 2:1. In another embodiment, the buffer to aluminum molar ratio is about 1: 1 to about 1.5:1.
  • compositions may be made in a variety of ways involving a stepwise procedure to neutralize aluminum chloride in solution (optionally buffered) using inorganic basic salts.
  • the procedure generally includes the step of heating an aqueous solution containing an aluminum chloride compound (optionally with a buffer agent) at a temperature of about 50 0 C to about 95°C to reflux for a period of time of about 1 hour to about 5 hours.
  • the solution has a buffer agent to aluminum molar ratio of about 0.1: 1 to about 3: 1.
  • an aqueous solution of an inorganic base is added to the heated solution to thereby obtain a pH adjusted aluminum salt solution having a hydroxide to aluminum molar ratio of about 1:1 to about 4:1.
  • a zirconium salt may also be added to the pH adjusted aluminum salt solution, hi one other such embodiment, the molar ratio of Al: Zr is about 5: 1 to about 10: 1.
  • the antiperspirant active composition has a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution.
  • an aqueous aluminum chloride salt solution is buffered with betaine monohydate and held at about 5O 0 C to about 95°C to reflux for a period time of about 1 to about 6 hours.
  • an aqueous solution of an inorganic base is added dropwise over a period of time of about 1 to about 3 hours while maintaining the aluminum- betaine solution at about 50 0 C to about 95 0 C to reflux.
  • the solution has a betaine to aluminum molar ratio of about 1.1.
  • the solution has a betaine to aluminum molar ratio of about 1.25.
  • a ZrOCl 2 solution is added to the pH adjusted aluminum- betaine solution.
  • the molar ratio of Al:Zr is about 8. In another such embodiment, the molar ratio of Al:Zr is about 7. In one other such embodiment, the molar ratio of Al:Zr is about 9.
  • an aqueous aluminum chloride solution is buffered with glycine and held at about 5O 0 C to about 95°C to reflux for a period time of about 1 to about 6 hours.
  • an aqueous solution of an inorganic base is added dropwise over a period of time of about 1 to about 3 hours while maintaining the aluminum-glycine solution at about 50 0 C to about 95°C to reflux.
  • the solution has an aluminum to glycine molar ratio of about 0.4.
  • the solution has an aluminum to glycine molar ratio of about 0.8.
  • a ZrOCl 2 solution is added to the pH adjusted aluminum- glycine solution.
  • the molar ratio of Al:Zr is about 8.
  • the molar ratio of Al:Zr is about 7.
  • the molar ratio of Al:Zr is about 9.
  • the aluminum chloride salt and inorganic base may be obtained from a variety of sources.
  • the aluminum chloride salt includes aluminum trichloride, aluminum chlorohexahydrate and aluminum dichlorohydrate.
  • the aluminum chloride salt is aluminum chlorohexahydrate.
  • the inorganic base can be at least one base chosen from metal hydroxides, calcium hydroxide, strontium hydroxide, barium hydroxide, metal oxides, calcium oxide, strontium oxide, and barium oxide.
  • the present invention provides for aluminum antiperspirant active compositions and/or aluminum-zirconium antiperspirant active compositions having high levels of low molecular weight Al and Zr species. As illustrated in Figures 2 to 7, the high levels of low molecular weight Al and Zr species is reflected in a SEC trace that has an intense Peak 4, low Peaks 1, 2, 3 and 5. The polymerization of the antiperspirant actives in aqueous solutions and the correspondent gelation process were followed by monitoring the molecular weight profile of the polyoxohalides in time by SEC. The relative retention time (“Kd”) for each of these peaks varies depending on the experimental conditions, but the peaks remain relative to each other.
  • Kd relative retention time
  • Data for Tables in the examples was obtained using an SEC chromatogram using the following parameters: Waters®600 analytical pump and controller, Rheodyne® 77251 injector, Protein-Pak® 125 (Waters) column, Waters 2414 Refractive Index Detector. 5.56mM nitric acid mobile phase, 0.50ml/min flow rate, 2.0 microliter injection volume. Data was analyzed using Water® Empower software (Waters Corporation, Milford, Mass.). The concentration of the antiperspirant in solution does not affect the retention time in the machine.
  • fp is the fraction of peak i
  • Pi or Pj are the intensity of peaks Pi or Pj, respectively.
  • the amount of low molecular weight Al species will be correlated with the fraction, fp 4 . or percentage, f P4 xlOO, of SEC-Peak 4.
  • a preferred antiperspirant salt would have a very low fpi, fpi, fp 3 . and/or fps, and a high fp 4 .
  • the ratio of Peak 4 to Peak 3 is at least 8, 9, 10, 11, 12, 13. 14. 15, 16. 17. 18, 19. 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100. or any number up to infinity.
  • an aluminum salt and/or aluminum-zirconium salt, in aqueous solution exhibit a SEC profile wherein the SEC Peak 4 to Peak 3 intensity ratio is at least 7.
  • the percentage of SEC Peak 4 of a total area of Peaks 1, 2, 3, 4, 5, and 6 in the SEC chromatogram is: at least 50%; at least 60%; at least 70%; at least 80%; at least 90%, or 95 to 100%.
  • the SEC Peak 4 area is 100%.
  • the aluminum salt and/or the aluminum-zirconium salt, in aqueous solution exhibits a SEC profile wherein the SEC Peak 4 to Peak 3 intensity ratio is at least 7 and exhibits low percentage of SEC Peak 3.
  • the composition has the percentage of SEC Peak 3 area of a total area of Peaks 1, 2, 3, 4. 5.
  • the composition has no SEC Peak 3 area.
  • the aluminum salt and/or the aluminum-zirconium salt, in aqueous solution exhibits a SEC profile wherein the SEC Peak 4 to Peak 3 intensity ratio is at least 7 and exhibits low percentages of SEC Peak 5.
  • the percentage of SEC Peak 5 area of a total area of Peaks 1, 2, 3, 4. 5. and 6 in the SEC chromatogram is: less than about 30 %; less than about 20 %; less than about 10 %; less than about 5 %; or less than about 1 %.
  • the composition has no SEC Peak 5 area.
  • the aluminum salt and/or the aluminum-zirconium salt, in aqueous solution exhibits a SEC profile wherein the SEC Peak 4 to Peak 3 ratio is at least 7, and exhibits a low percentage of SEC Peak 1 and a low percentage of SEC Peak 2.
  • 4, 5, and 6 in the SEC chromatogram is: less than about 10 %: a SEC Peak 1 area less than about 5 %; less than about 2 %; less than about 1 %; less than about 0.9 %; less than about 0.8 %; of less than about 0.7 %: less than about 0.6 %; less than about 0.5 %; less than about 0.4 %; less than about 0.3 %; less than about 0.2 %; or less than about 0.1 %.
  • the complex has no SEC Peak 1 area.
  • the percentage of SEC Peak 2 area of a total area of Peaks 1, 2, 3, 4, 5, and 6 in the SEC chromatogram is: less than about 10 %; less than about 5 %; less than about 2 %; less than about 1 %; less than about 0.9 %; less than about 0.8 %; less than about 0.7 %; less than about 0.6 %; less than about 0.5 %; less than about 0.4 %; less than about 0.3 %: less than about 0.2 %; or less than about 0.1 %.
  • the composition has no SEC Peak 2 area.
  • the aluminum antiperspirant active compositions and/or aluminum-zirconium antiperspirant active compositions may be used in a variety of antiperspirant products. If the product is used as a solid powder, the size of the particles of antiperspirant active of the invention can be any desired size, and may include conventional sizes such as in the range of 2 to 100 microns, with selected grades having an average particle size of 30-40 microns: finer sized grades having an average particle size distribution of 2-10 microns with an average size of about 7 microns as made by a suitable dry-grinding method; and micronized grades having an average particle size of less than about or equal to 2 microns, or less than about or equal to 1.5 microns.
  • compositions of this invention may be used to formulate antiperspirants having improved efficacy.
  • antiperspirants include solids such as sticks and creams (creams sometimes being included in the term "soft solid"), gels, liquids (such as are suitable for roll- on products), and aerosols.
  • the forms of these products may be suspensions or emulsions.
  • These antiperspirant actives can be used as the antiperspirant active in any antiperspirant composition.
  • Suitable formulations include the following:
  • Sticks-Stick products may be made with conventional gelling agents such as stearyl alcohol and dibenzylidene sorbitol.
  • a sample formulation is as follows:
  • antiperspirant active of the invention in solution form (25-45% actives on an anhydrous basis in water);
  • Soft solids may be made with formulations described in U.S. Patent No. 6.682,749. A sample formulation is as follows:
  • elastomer in cyclomethicone KSG- 15 from Shin-Etsu
  • 5-15% (particularly 6%) polyethylene for example, beads having a density in the range of 0.91-0.98 g/cm 3 and an average particle size in the range of 5-40 microns
  • Gels may be made with a variety of formulations such as:
  • dimethicone particularly with a viscosity of 100 centistokes
  • dimethicone copolyol for example, Dow Corning 2-5185 C (48%)
  • dimethicone copolyol for example, Dow Corning 2-5185C (48%)
  • elastomer in cyclomethicone for example, DC-9040 from Dow Corning Corporation
  • dimethicone copolyol for example, Dow Corning 2-5185 C (48%)
  • dimethicone copolyol for example, Dow Corning 2-5185 C (48%)
  • 40-60% elastomer in cyclomethicone for example, DC-9040 from Dow Corning Corporation
  • dimethicone copolyol for example, Dow Corning 2-5185C (48%)
  • cyclomethicone 60-70% elastomer in cyclomethicone (for example. DC-9040 from Dow Coming Corporation
  • dimethicone copolyol for example, Dow Corning 2-5185 C (48%):
  • dimethicone copolyol for example, Dow Corning 2-5185 C (48%)
  • cyclomethicone 40-50% elastomer in cyclomethicone (for example, DC-9040 from Dow Corning Corporation
  • dimethicone copolyol for example, Dow Corning 2-5185 C (48%)
  • cyclomethicone 40-50% elastomer in cyclomethicone (for example, DC-9040 from Dow Corning Corporation
  • the cosmetic composition according to the present invention can be packaged in conventional containers, using conventional techniques.
  • a gel, cream or soft-solid cosmetic composition is produced, the composition can be introduced into a dispensing package (for example, conventional packages for gels with glide on applicators, jars where the gel or cream is applied by hand, and newer style packages having a top surface with pores) as conventionally done in the art.
  • the product can be dispensed from the dispensing package as conventionally done in the art, to deposit the active material, for example, on the skin.
  • sprays, aerosols and roll-ons the compositions can be placed in a conventional types of container (with the inclusion of propellants in aerosols). This provides good deposition of the active material on the skin.
  • compositions of the present invention can be formulated as clear, translucent or opaque products.
  • a desired feature of the present invention is that a clear, or transparent, cosmetic composition, (for example, a clear or transparent deodorant or antiperspirant composition) can be provided.
  • the term clear or transparent according to the present invention is intended to connote its usual dictionary definition; thus, a clear liquid or gel antiperspirant composition of the present invention allows ready viewing of objects behind it.
  • a translucent composition although allowing light to pass through, causes the light to be scattered so that it will be impossible to see clearly objects behind the translucent composition.
  • An opaque composition does not allow light to pass there through.
  • a gel or stick is deemed to be transparent or clear if the maximum transmittance of light of any wavelength in the range 400-800 nm through a sample 1 cm thick is at least 35%, or at least 50%.
  • the gel or liquid is deemed translucent if the maximum transmittance of such light through the sample is between 2% and less than about 35%.
  • a gel or liquid is deemed opaque if the maximum transmittance of light is less than about 2%.
  • the transmittance can be measured by placing a sample of the aforementioned thickness into a light beam of a spectrophotometer whose working range includes the visible spectrum, such as a Bausch & Lomb Spectronic 88 Spectrophotometer. As to this definition of clear, see European Patent Application Publication No. 291.334 A2.
  • 10% solutions are prepared from commercially available antiperspirants.
  • the solutions are prepared by adding Ig of antiperspirant to 9g of water and mixing.
  • the antiperspirant salts were ReachTM 103, ReachTM 301 from Reheis, and SummitTM Z576 from Summit Research Labs.
  • a 0.72M A1C1 3 ' 6H 2 O (16.26 mmol) was buffered with 20 mmol anydrous betaine, held at 9O 0 C, and stirred vigorously.
  • a 4 N Ca (OH) 2 (20mmol) was added dropwise over a 2 hour period.
  • a ratio of OH:A1 of 2.46 was employed in an attempt increase the final pH and to reduce SEC-Peak 5 species. Because a higher OH:A1 ratio was used, the addition of the base was extended over a 2 hour period.
  • the pH after the reaction was 4.8.
  • the SEC chromatogram indicated that the solution contained exclusively SEC-Peak 4 310 antiperspirant active species. Substantially no SEC- Peak 3 species was observed at a retention time of approximately 15.5 minutes.
  • Example 2 A small portion of the solution from Example 2 is taken to determine the effects of Zr on the peak distribution.
  • ZrOCl 2 -SH 2 O is added to achieve a molar ratio of 8: 1 , Al:Zr.
  • the pH after adding Zr reduces to 3.7.
  • the SEC chromatogram of this zirconium, aluminum solution shows two notable features. Firstly, the SEC-Peak 4 remains the predominate peak, and the SEC-Peak 5 intensity increased to 1% - as expected by the reduced pH. Secondly, the SEC chromatogram does not show any peaks with retention time of 12.5 minute indicating the absence of undesirable Zr polymer species.
  • a 0.5M AlCl 3 -OH 2 O (25 mmol) is buffered with 62.5 mmol glycine, held at 95°C. and stirred vigorously.
  • a 1.0 N CA (OH) 2 (31.25 mmol) is added dropwise over a 1 hour period.
  • a ratio of OH:A1 of 2.5 is employed in an attempt to increase the final pH and to reduce the SEC-Peak 5 species.
  • the pH after the reaction is 4.52.
  • the SEC chromatogram shown in Figure 6 exhibits exclusively SEC-Peak 4 and no SEC-Peak 5. Substantially no SEC-Peak 3 species is observed at a retention time of approximately 15.5 minutes.
  • Example 5 A small portion of the solution from Example 5 is taken to determine the effects of Zr on the peak distribution.
  • ZrOCl 2 -SH 2 O is added to achieve an AhZr molar ratio of 8:1.
  • the pH after adding Zr reduces to 3.3.
  • the SEC chromatogram shown in Figure 7 exhibits primarily SEC-Peak 4 and substantially no SEC-Peak 5 (720). This data indicates that the pure SEC-Peak 4 solution of Example 5 does not promote the aggregation of Zr into larger, less efficacious species. Also substantially no SEC-Peak 3 species is observed at a retention time of approximately 15.5 minutes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

An antiperspirant active composition comprising an aluminum salt having an aluminum to chloride molar ratio of about 0.3:1 to about 3:1, exhibiting a SEC chromatogram having a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution. The composition can optionally include zirconium. Also, methods of making.

Description

TITLE
ANTIPERSPIRANT ACTIVE COMPOSITIONS HAVING SEC CHROMATOGRAM EXHIBITING HIGH SEC PEAK 4 INTENSITY
BACKGROUND
[0001] Antiperspirant salts, such as aluminum chlorohydrex (also called aluminum chlorohydrex polymeric salts and abbreviated here as "ACH") and aluminum zirconium glycine salts (abbreviated here as "ZAG", "ZAG complexes" or "AZG"), are known to contain a variety of polymeric and oligomeric species with molecular weights (MW) of 100- 500,000. It has been clinically shown that, in general, the smaller the species, the higher the efficacy for reducing sweat.
[0002] In an attempt to increase the quality and quantity of smaller aluminum and/or zirconium species, a number of efforts have focused on (1) how to select the components of ACH and ZAG that affect the performance of these materials as antiperspirants and (2) how to manipulate these components to obtain and/or maintain the presence of smaller types of these components. These attempts have included the development of analytical techniques to identify the components. Size exclusion chromatography ("SEC") or gel permeation chromatography ("GPC") are methods frequently used for obtaining information on polymer distribution in antiperspirant salt solutions. With appropriate chromatographic columns, generally five distinctive groups of polymer species can be detected in commercial ACH and ZAG complexes appearing in a chromatogram as peaks 1, 2. 3, 4 and a peak known as "5.6". Peak 1 is the larger Zr species (greater than 60 Angstroms). Peaks 2 and 3 are larger aluminum species. Peak 4 is smaller aluminum species (aluminum oligomers, or small aluminum cluster) and has been correlated with enhanced efficacy for both Al and Al/Zr salts. Peak 5, 6 is the smallest aluminum species. Various analytical approaches for characterizing the peaks of ACH and various types of ZAG actives are found in "Antiperspirant Actives-Enhanced Efficacy Aluminum-Zirconium-Glycine (AZG) Salts" by Dr. Allan H. Rosenberg (Cosmetics and Toiletries Worldwide, Fondots, D. C. ed., Hartfordshire. UK: Aston Publishing Group, 1993, pages 252. 254-256).
[0003] Attempts to activate antiperspirant salts to produce materials having improved efficacy have included developing processes for obtaining composition having large amounts of Peak 4 species. None of these efforts, however, have resulted in an antiperspirant composition having a composition with little or no Peak 3 and optionally little or no Peak 5. SUMMARY OF INVENTION
[0004] The present invention provides for an antiperspirant active composition comprising an aluminum salt having an aluminum to chloride molar ratio of about 0.3: 1 to about 3: 1, exhibiting a SEC chromatogram having a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution, and optionally including zirconium.
[0005] The present invention also provides for a method of making an antiperspirant active composition that exhibits a SEC chromatogram having a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution comprising:
I) heating an aqueous solution containing an aluminum salt having an aluminum to chloride molar ratio of about 0.3: 1 to about 3: 1. optionally with a buffer agent, at a temperature of about 500C to about 95°C to reflux for a period of time of about 1 hour to about 5 hours to obtain an aluminum salt solution;
II) adding an aqueous solution of an inorganic base to obtain an aluminum salt solution having an OH:A1 molar ratio of about 2:1 to about 2.6:1 to obtain a pH adjusted aluminum salt solution having a pH of about 2 to about 5; and
III) optionally adding an aqueous solution containing a zirconium compound to the pH adjusted aluminum salt solution to thereby obtain an aluminum-zirconium salt solution having a molar ratio of aluminum to zirconium of about 5: 1 to about 10:1.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] The accompanying drawings, which are included to provide further understanding of the disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments of the disclosure and. together with the description, serve to explain the principles of the disclosure.
[0008] Figure 1 illustrates an SEC chromatogram of a prior art antiperspirant active composition.
[0009] Figure 2 illustrates an SEC chromatogram having exclusive peaks 4 and 5 for an inventive product. Example 1 , of the present invention.
[0010] Figure 3 illustrates an SEC chromatogram having exclusive peak 4 for an inventive product. Example 2, of the present invention. [0011] Figure 4 illustrates an SEC chromatogram having exclusive peaks 4 and 5 for an inventive product. Example 3, of the present invention.
[0012] Figure 5 illustrates an SEC chromatogram having exclusive peaks 4 and 5 for an inventive product, Example 4, of the present invention.
[0013] Figure 6 illustrates an SEC chromatogram having exclusive peak 4 for an inventive product. Example 5, of the present invention.
[0014] Figure 7 illustrates an SEC chromatogram having exclusive peaks 4 and 5 for an inventive product, Example 6, of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0016] As used throughout, ranges are used as a shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range.
[0017] The present invention is directed to an antiperspirant active composition having a high SEC peak 4 in aqueous solution. The composition is obtained by a stepwise procedure to neutralize aluminum chloride in a solution (optionally buffered) using inorganic bases. The antiperspirant active compositions obtained by this stepwise procedure include aluminum salts having an aluminum to chloride molar ratio of about 0.3:1 to about 3:1. the aluminum salt has a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution. The composition may optionally include zirconium.
[0018] Optionally, a buffer can be included. Buffers that can be used can be chosen from amino acids, glycine, and betaine. The buffer to aluminum molar ratio in certain embodiments can be about 0.1 :1 to about 3:1. In another embodiment, the buffer to aluminum molar ratio is about 0.5:1 to about 2:1. In another embodiment, the buffer to aluminum molar ratio is about 1: 1 to about 1.5:1.
[0019] The compositions may be made in a variety of ways involving a stepwise procedure to neutralize aluminum chloride in solution (optionally buffered) using inorganic basic salts. The procedure generally includes the step of heating an aqueous solution containing an aluminum chloride compound (optionally with a buffer agent) at a temperature of about 500C to about 95°C to reflux for a period of time of about 1 hour to about 5 hours. The solution has a buffer agent to aluminum molar ratio of about 0.1: 1 to about 3: 1. To adjust the pH of the aluminum salt solution, an aqueous solution of an inorganic base is added to the heated solution to thereby obtain a pH adjusted aluminum salt solution having a hydroxide to aluminum molar ratio of about 1:1 to about 4:1. and a pH of about 2 to about 5. In one such embodiment, the hydroxide to aluminum molar ratio of about 2:1 to about 3:1. In another such embodiment, the hydroxide to aluminum molar ratio is about 2.1 :1 to about 2.6: 1. A zirconium salt may also be added to the pH adjusted aluminum salt solution, hi one other such embodiment, the molar ratio of Al: Zr is about 5: 1 to about 10: 1. The antiperspirant active composition has a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution.
[0020] In one embodiment, an aqueous aluminum chloride salt solution is buffered with betaine monohydate and held at about 5O0C to about 95°C to reflux for a period time of about 1 to about 6 hours. To the heated solution, an aqueous solution of an inorganic base is added dropwise over a period of time of about 1 to about 3 hours while maintaining the aluminum- betaine solution at about 500C to about 950C to reflux. In one such embodiment, the solution has a betaine to aluminum molar ratio of about 1.1. In another such embodiment, the solution has a betaine to aluminum molar ratio of about 1.25.
[0021] In another embodiment, a ZrOCl2 solution is added to the pH adjusted aluminum- betaine solution. In one such embodiment, the molar ratio of Al:Zr is about 8. In another such embodiment, the molar ratio of Al:Zr is about 7. In one other such embodiment, the molar ratio of Al:Zr is about 9.
[0022] In another embodiment, an aqueous aluminum chloride solution is buffered with glycine and held at about 5O0C to about 95°C to reflux for a period time of about 1 to about 6 hours. To the heated solution, an aqueous solution of an inorganic base is added dropwise over a period of time of about 1 to about 3 hours while maintaining the aluminum-glycine solution at about 500C to about 95°C to reflux. In one such embodiment, the solution has an aluminum to glycine molar ratio of about 0.4. hi another such embodiment, the solution has an aluminum to glycine molar ratio of about 0.8.
[0023] In another embodiment, a ZrOCl2 solution is added to the pH adjusted aluminum- glycine solution. In one such embodiment, the molar ratio of Al:Zr is about 8. In another such embodiment, the molar ratio of Al:Zr is about 7. In one other such embodiment, the molar ratio of Al:Zr is about 9. [0024] For the above methods, the aluminum chloride salt and inorganic base may be obtained from a variety of sources. In one embodiment, the aluminum chloride salt includes aluminum trichloride, aluminum chlorohexahydrate and aluminum dichlorohydrate. In one such embodiment, the aluminum chloride salt is aluminum chlorohexahydrate.
[0025] In one embodiment, the inorganic base can be at least one base chosen from metal hydroxides, calcium hydroxide, strontium hydroxide, barium hydroxide, metal oxides, calcium oxide, strontium oxide, and barium oxide.
[0026] The present invention provides for aluminum antiperspirant active compositions and/or aluminum-zirconium antiperspirant active compositions having high levels of low molecular weight Al and Zr species. As illustrated in Figures 2 to 7, the high levels of low molecular weight Al and Zr species is reflected in a SEC trace that has an intense Peak 4, low Peaks 1, 2, 3 and 5. The polymerization of the antiperspirant actives in aqueous solutions and the correspondent gelation process were followed by monitoring the molecular weight profile of the polyoxohalides in time by SEC. The relative retention time ("Kd") for each of these peaks varies depending on the experimental conditions, but the peaks remain relative to each other. Data for Tables in the examples was obtained using an SEC chromatogram using the following parameters: Waters®600 analytical pump and controller, Rheodyne® 77251 injector, Protein-Pak® 125 (Waters) column, Waters 2414 Refractive Index Detector. 5.56mM nitric acid mobile phase, 0.50ml/min flow rate, 2.0 microliter injection volume. Data was analyzed using Water® Empower software (Waters Corporation, Milford, Mass.). The concentration of the antiperspirant in solution does not affect the retention time in the machine.
[0027] The design of modern AP salts aims at actives with high levels of low molecular weight Al and Zr species, which is reflected in a SEC trace that has intense Peak 4 and low Peaks 1, 2, and 3. Throughout the present study, the levels of the species corresponding to these peaks are estimated based on the following ratios (or percentages):
fPi = ζ^. / = 1, 2, 3. 4, 5; j = 2, 3, 4, 5
where fp, is the fraction of peak i, and Pi or Pj are the intensity of peaks Pi or Pj, respectively. The amount of low molecular weight Al species will be correlated with the fraction, fp4. or percentage, fP4 xlOO, of SEC-Peak 4. In brief, a preferred antiperspirant salt would have a very low fpi, fpi, fp3. and/or fps, and a high fp4.
[0028] In certain embodiments, the ratio of Peak 4 to Peak 3 is at least 8, 9, 10, 11, 12, 13. 14. 15, 16. 17. 18, 19. 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100. or any number up to infinity.
[0029] In one embodiment, an aluminum salt and/or aluminum-zirconium salt, in aqueous solution, exhibit a SEC profile wherein the SEC Peak 4 to Peak 3 intensity ratio is at least 7. In such embodiments, the percentage of SEC Peak 4 of a total area of Peaks 1, 2, 3, 4, 5, and 6 in the SEC chromatogram is: at least 50%; at least 60%; at least 70%; at least 80%; at least 90%, or 95 to 100%. In another such embodiment, the SEC Peak 4 area is 100%.
[0030] In another embodiment, the aluminum salt and/or the aluminum-zirconium salt, in aqueous solution, exhibits a SEC profile wherein the SEC Peak 4 to Peak 3 intensity ratio is at least 7 and exhibits low percentage of SEC Peak 3. In such embodiments, the composition has the percentage of SEC Peak 3 area of a total area of Peaks 1, 2, 3, 4. 5. and 6 in the SEC chromatogram is: less than about 10 %; less than about 5 %: less than about 2 %; less than about 1 %; less than about 0.9 %; less than about 0.8 %; less than about 0.7 %; less than about 0.6 %; of less than about 0.5 %; less than about 0.4 %: less than about 0.3 %; less than about 0.2 %; or less than about 0.1 %. In another such embodiment, the composition has no SEC Peak 3 area.
[0031] In another embodiment, the aluminum salt and/or the aluminum-zirconium salt, in aqueous solution, exhibits a SEC profile wherein the SEC Peak 4 to Peak 3 intensity ratio is at least 7 and exhibits low percentages of SEC Peak 5. In such embodiments, the percentage of SEC Peak 5 area of a total area of Peaks 1, 2, 3, 4. 5. and 6 in the SEC chromatogram is: less than about 30 %; less than about 20 %; less than about 10 %; less than about 5 %; or less than about 1 %. In another such embodiment, the composition has no SEC Peak 5 area.
[0032] In another embodiment, the aluminum salt and/or the aluminum-zirconium salt, in aqueous solution, exhibits a SEC profile wherein the SEC Peak 4 to Peak 3 ratio is at least 7, and exhibits a low percentage of SEC Peak 1 and a low percentage of SEC Peak 2. In such embodiment, the percentage of SEC Peak 1 area of a total area of Peaks 1. 2, 3. 4, 5, and 6 in the SEC chromatogram is: less than about 10 %: a SEC Peak 1 area less than about 5 %; less than about 2 %; less than about 1 %; less than about 0.9 %; less than about 0.8 %; of less than about 0.7 %: less than about 0.6 %; less than about 0.5 %; less than about 0.4 %; less than about 0.3 %; less than about 0.2 %; or less than about 0.1 %. In another embodiment, the complex has no SEC Peak 1 area. In another embodiment, the percentage of SEC Peak 2 area of a total area of Peaks 1, 2, 3, 4, 5, and 6 in the SEC chromatogram is: less than about 10 %; less than about 5 %; less than about 2 %; less than about 1 %; less than about 0.9 %; less than about 0.8 %; less than about 0.7 %; less than about 0.6 %; less than about 0.5 %; less than about 0.4 %; less than about 0.3 %: less than about 0.2 %; or less than about 0.1 %. In another embodiment, the composition has no SEC Peak 2 area.
[0033] The aluminum antiperspirant active compositions and/or aluminum-zirconium antiperspirant active compositions may be used in a variety of antiperspirant products. If the product is used as a solid powder, the size of the particles of antiperspirant active of the invention can be any desired size, and may include conventional sizes such as in the range of 2 to 100 microns, with selected grades having an average particle size of 30-40 microns: finer sized grades having an average particle size distribution of 2-10 microns with an average size of about 7 microns as made by a suitable dry-grinding method; and micronized grades having an average particle size of less than about or equal to 2 microns, or less than about or equal to 1.5 microns.
[0034] The compositions of this invention may be used to formulate antiperspirants having improved efficacy. Such antiperspirants include solids such as sticks and creams (creams sometimes being included in the term "soft solid"), gels, liquids (such as are suitable for roll- on products), and aerosols. The forms of these products may be suspensions or emulsions. These antiperspirant actives can be used as the antiperspirant active in any antiperspirant composition.
[0035] Examples of suitable formulations include the following:
[0036] Sticks-Stick products may be made with conventional gelling agents such as stearyl alcohol and dibenzylidene sorbitol. A sample formulation is as follows:
40-55% (particularly 45%); cyclomethicone (especially D5 cyclomethicone);
20-30% (particularly 21%); stearyl alcohol 7-15% (particularly 10%); talc 15-22% (particularly 22%); and antiperspirant active of the invention in particle form; and
1-3% (particularly 2%) fragrance. [0037] Roll Ons having a sample formulation:
45-65% (particularly 55%) cyclomethicone (especially D5 cyclomethicone):
0.1-10% (particularly 3%) cyclomethicone/dimethicone copolyol (such as Dow Coming
2-5185C) 10-25% (particularly 20%); antiperspirant active of the invention in solution form (25-45% actives on an anhydrous basis in water);
5-30% (particularly 20%) water; and
1-3% (particularly 2%) fragrance.
[0038] Soft solids— Soft solids may be made with formulations described in U.S. Patent No. 6.682,749. A sample formulation is as follows:
40-70% (particularly 50%) elastomer in cyclomethicone (KSG- 15 from Shin-Etsu); 5-15% (particularly 6%) polyethylene (for example, beads having a density in the range of 0.91-0.98 g/cm3 and an average particle size in the range of 5-40 microns)-. 10-20% (particularly 15%) C12-15 alkylbenzoate (FINSOLV™ TN from Finetex): 0.1-25%% (particularly 22%) antiperspirant active of the invention in powder form; 1-15% (particularly 5%) dimethicone (particularly with a viscosity of 100 centistokes); and 1-3% (particularly 2%) fragrance.
[0039] Gels— Gels may be made with a variety of formulations such as:
5-50% (particularly 29%) cyclomethicone (particularly D5);
0.1-10% (particularly 3%) cyclomethicone/dimethicone copolyol (such as Dow Coming
2-5185C):
0-10% (particularly 5%) hydrogenated polyisobutene 250;
0-10% (particularly 5%) C12-15 alkylbenzoate (FINSOLV™ TN from Finetex);
0-10% (particularly 5%) dimethicone (particularly with a viscosity of 100 centistokes);
0.1-25% (particularly 20%) antiperspirant active of the invention in powder form or 10-25%
(particularly 20%) of active in solution (25-45% actives on an anhydrous basis);
5-50% (particularly 30%) water; and
1-3% (particularly 2%) fragrance.
[0040] Note that in the explanation of the invention, where water is listed it is intended to count the contribution of the water present in the antiperspirant solution as part of the overall water content. Thus, water is sometimes listed as part of the actives solution or sometimes listed separately. [0041] In one embodiment the refractive indices of the external and internal phases are matched within 0.005 to obtain a clear product.
[0042] Other formulations of interest include:
[0043] Formulation A:
0.5-2.5% dimethicone copolyol (for example, Dow Corning 2-5185 C (48%));
55-65% elastomer in cyclomethicone (for example. DC-9040 from Dow Coming Corporation
(Midland, Mich.) or KSG- 15 from Shin-Etsu Silicones of America (Akron, Ohio));
1-10% PPG-3 myristyl ether;
10-25% antiperspirant active of the invention;
10-25% water; and
0.5-1.5% fragrance.
[0044] Formulation B:
1.0-3.0% dimethicone copolyol (for example, Dow Corning 2-5185C (48%)) 40-60% elastomer in cyclomethicone (for example, DC-9040 from Dow Corning Corporation
(Midland, Mich.) or KSG- 15 from Shin-Etsu Silicones of America (Akron, Ohio));
1-5% cyclomethicone (in addition to that found in the elastomer);
4-12% PPG-3 myristyl ether;
15-30% antiperspirant active of the invention;
15-35% water, and
0.5-1.5% fragrance.
[0045] Formulation C:
1.0-3.0% dimethicone copolyol (for example, Dow Corning 2-5185 C (48%));
1-10% hydrogenated polyisobutene (for example. Fancol™. Polyiso 250);
40-55% elastomer in cyclomethicone (for example, DC-9040 from Dow Corning Corporation
(Midland, Mich.) or KSG- 15 from Shin-Etsu Silicones of America (Akron, Ohio));
3-8% PPG-3 myristyl ether;
15-20% antiperspirant active of the invention;
20-30% water; and
1.0-3.0% fragrance.
[0046] Formulation D:
1.0-3.0% dimethicone copolyol (for example, Dow Corning 2-5185 C (48%)): 40-60% elastomer in cyclomethicone (for example, DC-9040 from Dow Corning Corporation
(Midland, Mich.) or KSG- 15 from Shin-Etsu Silicones of America (Akron. Ohio));
3-8% PPG-3 myristyl ether;
15-30% antiperspirant active of the invention;
15-30% water;
0.5-1.5% fragrance; and
1-10% diethylhexyl naphlhalate
[0047] Formulation E:
0.5-2.5% dimethicone copolyol (for example, Dow Corning 2-5185C (48%));
60-70% elastomer in cyclomethicone (for example. DC-9040 from Dow Coming Corporation
(Midland, Mich.) or KSG-15 from Shin-Etsu Silicones of America (Akron, Ohio));
7-10% antiperspirant active of the invention;
25-35% water;
1-10% methylpropylene diol (MPDiol) : and
0.5-1.5% fragrance
[0048] Formulation F:
1.0-3.0% dimethicone copolyol (for example, Dow Corning 2-5185 C (48%)):
6-10% hydrogenated polyisobutene (for example. FANCOL™ Polyiso 250);
35-45% elastomer in cyclomethicone (for example, DC-9040 from Dow Corning Corporation
(Midland. Mich.) or KSG-15 from Shin-Etsu Silicones of America (Akron, Ohio));
6-10% PPG-3 myristyl ether;
40-50% antiperspirant active of the invention as 43% active in water no additional water; and
0.5-1.0% fragrance.
[0049] Formulation G
0.1-0.6% dimethicone copolyol (for example, Dow Corning 2-5185 C (48%));
4-7% hydrogenated polyisobutene (for example, FANCOL™ Polyiso 250):
40-50% elastomer in cyclomethicone (for example, DC-9040 from Dow Corning Corporation
(Midland, Mich.) or KSG-15 from Shin-Etsu Silicones of America (Akron, Ohio));
4-7% PPG-3 myristyl ether;
40-50% antiperspirant active of the invention as 43% active in water no additional water; and
0.5-1.0% fragrance. [0050] Formulation H:
0.5-2.0% dimethicone copolyol (for example, Dow Corning 2-5185 C (48%));
1-7% hydrogenated polyisobutene (for example, FANCOL™ Polyiso 250);
40-50% elastomer in cyclomethicone (for example, DC-9040 from Dow Corning Corporation
(Midland, Mich.) or KSG- 15 from Shin-Etsu Silicones of America (Akron, Ohio)):
45-55% antiperspirant active as 43% active of the invention in water no additional water; and
0.5-1.5% fragrance.
[0051] Formulation I:
2-7% dimethicone copolyol (for example, Dow Corning 2-5185 C (48%));
0.1-1% Oleath-20 1-5% C 12-15 alkyl benzoate (FINSOLV™ TN):
15-25% elastomer in cyclomethicone (for example, DC-9040 from Dow Corning Corporation
(Midland. Mich.) or KSG- 15 from Shin-Etsu Silicones of America (Akron, Ohio));
15-25% antiperspirant active of the present invention;
15-30% water; and
0.5-1.5% fragrance
[0052] The cosmetic composition according to the present invention can be packaged in conventional containers, using conventional techniques. Where a gel, cream or soft-solid cosmetic composition is produced, the composition can be introduced into a dispensing package (for example, conventional packages for gels with glide on applicators, jars where the gel or cream is applied by hand, and newer style packages having a top surface with pores) as conventionally done in the art. Thereafter, the product can be dispensed from the dispensing package as conventionally done in the art, to deposit the active material, for example, on the skin. For sticks, sprays, aerosols and roll-ons the compositions can be placed in a conventional types of container (with the inclusion of propellants in aerosols). This provides good deposition of the active material on the skin.
[0053] Compositions of the present invention can be formulated as clear, translucent or opaque products. A desired feature of the present invention is that a clear, or transparent, cosmetic composition, (for example, a clear or transparent deodorant or antiperspirant composition) can be provided. The term clear or transparent according to the present invention is intended to connote its usual dictionary definition; thus, a clear liquid or gel antiperspirant composition of the present invention allows ready viewing of objects behind it. By contrast, a translucent composition, although allowing light to pass through, causes the light to be scattered so that it will be impossible to see clearly objects behind the translucent composition. An opaque composition does not allow light to pass there through. Within the context of the present invention, a gel or stick is deemed to be transparent or clear if the maximum transmittance of light of any wavelength in the range 400-800 nm through a sample 1 cm thick is at least 35%, or at least 50%. The gel or liquid is deemed translucent if the maximum transmittance of such light through the sample is between 2% and less than about 35%. A gel or liquid is deemed opaque if the maximum transmittance of light is less than about 2%. The transmittance can be measured by placing a sample of the aforementioned thickness into a light beam of a spectrophotometer whose working range includes the visible spectrum, such as a Bausch & Lomb Spectronic 88 Spectrophotometer. As to this definition of clear, see European Patent Application Publication No. 291.334 A2. Thus, according to the present invention, there are differences between transparent (clear), translucent and opaque compositions.
EXAMPLES [0054] Comparative Example
[0055] A 0.72 M AlCl 3 '6H20 (18 mmol) is held at 9O0C and stirred vigorously. To this solution, a 4 N Ca(OH)2 (20 mmol) is added dropwise over a 1 hour 30 minute period. A ratio of OH:A1 of 2.22 is employed in an attempt to prevent the formation of larger unwanted Al species. The pH after the reaction was 2.36 due to the low OH: Al ratio. The SEC chromatogram, illustrated in Figure 1, exhibits multiple peaks including. SEC-Peak 4, and SEC-Peak 5 indicating multiple Al species are present in solution. At a retention time of approximately 15.5 minutes, SEC-Peak 3 is observed.
[0056] Also for comparison, 10% solutions are prepared from commercially available antiperspirants. The solutions are prepared by adding Ig of antiperspirant to 9g of water and mixing. The antiperspirant salts were Reach™ 103, Reach™ 301 from Reheis, and Summit™ Z576 from Summit Research Labs.
[0057] Example 1
[0058] A 0.72M AlCl3-OH2O (18 mmol) is buffered with 20 mmol betaine monohydrate. held at 900C, and stirred vigorously. To this solution, a 4 N Ca(OH)2 (20 mmol) is added dropwise over a 1 hour 30 minute period. A ratio of OH: Al of 2.22 is employed in an attempt to prevent the formulation of large Al species. The pH after the reaction is 2.56 due the low OH:A1 ratio. As illustrated in Figure 2, the SEC chromatogram shows exclusively SEC-Peak 4 and SEC-Peak 5, which are known to represent active anti-perspirant species. Substantially no SEC-Peak 3 species is observed at a retention time of approximately 15.5 minutes.
[0059] Example 2
[0060] A 0.72M A1C13 '6H2O (16.26 mmol) was buffered with 20 mmol anydrous betaine, held at 9O0C, and stirred vigorously. To this solution, a 4 N Ca (OH)2 (20mmol) was added dropwise over a 2 hour period. A ratio of OH:A1 of 2.46 was employed in an attempt increase the final pH and to reduce SEC-Peak 5 species. Because a higher OH:A1 ratio was used, the addition of the base was extended over a 2 hour period. The pH after the reaction was 4.8. As illustrated in Figure 3, the SEC chromatogram indicated that the solution contained exclusively SEC-Peak 4 310 antiperspirant active species. Substantially no SEC- Peak 3 species was observed at a retention time of approximately 15.5 minutes.
[0061] Example 3
[0062] A small portion of the solution from Example 2 is taken to determine the effects of Zr on the peak distribution. ZrOCl2-SH2O is added to achieve a molar ratio of 8: 1 , Al:Zr. The pH after adding Zr reduces to 3.7. As shown in Figure 4, the SEC chromatogram of this zirconium, aluminum solution shows two notable features. Firstly, the SEC-Peak 4 remains the predominate peak, and the SEC-Peak 5 intensity increased to 1% - as expected by the reduced pH. Secondly, the SEC chromatogram does not show any peaks with retention time of 12.5 minute indicating the absence of undesirable Zr polymer species. The absence of this SEC-Peak indicates that the pure SEC-Peak 4 solution of Example 2 did not promote the aggregation of Zr into larger, less efficacious species. Also substantially no SEC-Peak 3 species is observed at a retention time of approximately 15.5 minutes.
[0063] Example 4
[0064] A 0.5M AlCl3-OH2O (25 mmol) is buffered with 31.25 mmol glycine, held at 95°C, and stirred vigorously. To this buffered solution, a 1.0 N Ca (OH)2 (31.25 mmol) is added dropwise over a 1 hour period. A ratio of OH:A1 of 2.5 is employed in an attempt to increase the final pH and to reduce SEC-Peak 5 species. The pH after the reaction is 4.52. The SEC chromatogram shown in Figure 5 exhibits primarily SEC-Peak 4 and a smaller SEC-Peak 5 (520). Substantially no SEC-Peak 3 species is observed at a retention time of approximately 15.5 minutes. [0065] Example 5
[0066] A 0.5M AlCl3-OH2O (25 mmol) is buffered with 62.5 mmol glycine, held at 95°C. and stirred vigorously. To this buffered solution a 1.0 N CA (OH)2 (31.25 mmol) is added dropwise over a 1 hour period. A ratio of OH:A1 of 2.5 is employed in an attempt to increase the final pH and to reduce the SEC-Peak 5 species. The pH after the reaction is 4.52. The SEC chromatogram shown in Figure 6 exhibits exclusively SEC-Peak 4 and no SEC-Peak 5. Substantially no SEC-Peak 3 species is observed at a retention time of approximately 15.5 minutes.
[0067] Example 6
[0068] A small portion of the solution from Example 5 is taken to determine the effects of Zr on the peak distribution. ZrOCl2-SH2O is added to achieve an AhZr molar ratio of 8:1. The pH after adding Zr reduces to 3.3. The SEC chromatogram shown in Figure 7 exhibits primarily SEC-Peak 4 and substantially no SEC-Peak 5 (720). This data indicates that the pure SEC-Peak 4 solution of Example 5 does not promote the aggregation of Zr into larger, less efficacious species. Also substantially no SEC-Peak 3 species is observed at a retention time of approximately 15.5 minutes.
Figure imgf000015_0001

Claims

What is claimed:
1. An antiper spirant active composition comprising an aluminum salt having an aluminum to chloride molar ratio of about 0.3: 1 to about 3: 1 , exhibiting a SEC chromatogram having a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution.
2. The antiperspirant active of claim 1, wherein the composition further comprises zirconium.
3. The antiperspirant active of claim 1, wherein the aluminum salt is buffer free and has an OH to Al ratio of about 2: 1 to about 2.6: 1.
4. The antiperspirant active of claim 1 further comprising a buffer, wherein a molar ratio of buffer to aluminum is about 0.1:1 to about 3: 1.
5. The antiperspirant active of claim 4, wherein the buffer is at least one buffer chosen from an amino acid, glycine, and betaine.
6. The antiperspirant active of claim 1, wherein the zirconium is present and a molar ratio of aluminum to zirconium is about 5:1 to about 10: 1.
7. The antiperspirant active composition of claim 1, wherein the composition has a SEC Peak 4 area of at least 50% of a total area of Peaks 1, 2, 3, 4, 5, and 6 in the SEC chromatogram.
8. The antiperspirant active composition of claim 1, wherein the composition has a SEC Peak 4 area of 95 to 100% of a total area of Peaks 1 , 2, 3, 4, 5, and 6 in the SEC chromatogram.
9. The antiperspirant active composition of claim 1, wherein the composition has a SEC Peak 3 area of less than about 10 % of a total area of Peaks 1, 2, 3. 4, 5, and 6 in the SEC chromatogram.
10. The antiperspirant active composition of claim 1, wherein the composition has no SEC Peak 3 area in the SEC chromatogram.
11. The antiperspirant active composition of claim 1, wherein the composition has a SEC Peak 5 area of less than about 30 % of a total area of Peaks 1, 2. 3, 4, 5, and 6 In the SEC chromatogram.
12. The antiperspirant active composition of claim 1, wherein the composition has no SEC Peak 5 area in the SEC chromatogram.
13. The antiperspirant active composition of claim 1, wherein the composition has a SEC Peak 1 area of less than about 10 % and a SEC Peak 2 area of less than about 10 % of a total area of Peaks 1 , 2, 3, 4. 5. and 6 Ln the SEC chromatogram.
14. The antiperspirant active composition of claim 1, wherein the composition has a SEC Peak 4 area of 95 to 100%, no SEC Peak 3 area, and no SEC Peak 5 area of a total area of Peaks 1, 2, 3, 4, 5, and 6 in the SEC chromatogram.
15. A method of making an antiperspirant active composition comprising:
I) heating an aqueous solution containing an aluminum salt having an aluminum to chloride molar ratio of about 0.3: 1 to about 3: 1, optionally with a buffer agent, at a temperature of about 500C to about 95°C to reflux for a period of time of about 1 hour to about 5 hours to obtain an aluminum salt solution:
II) adding an aqueous solution of an inorganic base to obtain an aluminum salt solution having an OH: Al molar ratio of about 2:1 to about 2.6: 1 to obtain a pH adjusted aluminum salt solution having a pH of about 2 to about 5; and
III) optionally adding an aqueous solution containing a zirconium compound to the pH adjusted aluminum salt solution to thereby obtain an aluminum- zirconium salt solution having a molar ratio of aluminum to zirconium of about 5:1 to about 10: 1.
16. The method of claim 15, wherein the buffer is present in a molar ratio of buffer to aluminum is about 0.1:1 to about 3: 1.
17. The method of claim 15, wherein the buffer agent is at least one buffer chosen from an amino acid, glycine, and betaine.
18. The method of claim 15, wherein the inorganic base includes at least one member chosen from metal hydroxides, calcium hydroxide, strontium hydroxide, barium hydroxide, metal oxides, calcium oxide, strontium oxide, and barium oxide.
19. The method of claim 15, wherein the aluminum chloride compound is chosen from aluminum trichloride, aluminum chlorohexahydrate, and aluminum dichlorohydrate.
20. The method of claim 15, wherein the composition further comprises zirconium.
21. The method of claim 20. wherein the zirconium is ZrOCb-δHiO.
22. The method of clam 15, wherein the antiperspirant active composition exhibits a SEC chromatogram having a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution.
23. The method of claim 22, wherein the antiperspirant active composition has a SEC Peak 4 area of at least 50% of a total area of Peaks 1, 2, 3, 4, 5, and 6 in the SEC chromatogram.
24. The method of claim 22, wherein the antiperspirant active composition has a SEC Peak 4 area of 95 to 100% of the total area of Peaks 1 , 2, 3, 4, 5, and 6 in the SEC chromatogram.
25. The method of claim 22, wherein the antiperspirant active composition has a SEC Peak 3 area of less than about 10 % of the total area of Peaks 1 , 2. 3, 4. 5. and 6 in the SEC chromatogram.
26. The method of claim 22, wherein the antiperspirant active composition has no SEC Peak 3 area.
27. The method of claim 22, wherein the antiperspirant active composition has a SEC Peak 5 area of less than about 30 % of the total area of Peaks 1 , 2. 3, 4, 5, and 6.
28. The method of claim 22, wherein the antiperspirant active composition has no SEC Peak 5 area.
29. The method of claim 22, wherein the antiperspirant active composition has a SEC Peak 1 area of less than about 10 % and a SEC Peak 2 area of less than about 10 % of the total area of Peaks 1 , 2, 3, 4, 5, and 6.
30. The method of claim 22, wherein the composition has a SEC Peak 4 area of 95 to 100%, no SEC Peak 3 area, and no SEC Peak 5 area of a total area of Peaks 1. 2, 3, 4, 5, and 6 in the SEC chromatogram.
PCT/US2007/087145 2007-12-12 2007-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity Ceased WO2009075678A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
PCT/US2007/087145 WO2009075678A1 (en) 2007-12-12 2007-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
US11/917,863 US20100202993A1 (en) 2007-12-12 2007-12-12 Antiperspirant Active Compositions Having SEC Chromatogram Exhibiting High SEC Peak 4 Intensity
ARP080105388A AR069657A1 (en) 2007-12-12 2008-12-11 ANTITRANSPIRANT ACTIVE COMPOSITIONS THAT HAVE A SEC CHROMATOGRAM THAT EXHIBITS HIGH INTENSITY OF PICO SEC 4 AND METHOD TO PREPARE THEM
CL2008003684A CL2008003684A1 (en) 2007-12-12 2008-12-11 Pharmaceutical composition comprising an aluminum salt, having a molar ratio of aluminum to chloride from about 0.3: 1 to 3: 1, further comprising zirconium; method of preparing the composition; use as an antiperspirant.
EP14155256.2A EP2810638B1 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
CN201410003540.5A CN103690384B (en) 2007-12-12 2008-12-12 There is the antiperspirant active compositions of the SEC chromatograph showing high sec peak semi-finals degree
CN200880120390.9A CN101896156B (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having SEC chromatograms exhibiting high sec peak 4 intensity
MX2010006370A MX2010006370A (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity.
CA2799270A CA2799270C (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
US12/446,045 US8257689B2 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
RU2010128580/15A RU2440092C1 (en) 2007-12-12 2008-12-12 Compositions with antiperspirant activity having sec chromatogram showing high peak intensity 4 sec
AU2008335029A AU2008335029B2 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having SEC chromatogram exhibiting high SEC Peak 4 intensity
ES08859061.7T ES2584256T3 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having SEC chromatogram presenting high intensity of SEC Peak 4
EP14155272.9A EP2740465A3 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having SEC chomatogram exhibiting high SEC peak 4 intensity
EP08859061.7A EP2229136B1 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
CA2706142A CA2706142C (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
CN201210413932.XA CN103083195B9 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions with the SEC chromatograms for showing high sec peaks semi-finals degree
PCT/US2008/086556 WO2009076591A1 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
CN201210413190.0A CN102920610B (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having SEC chromatograms exhibiting high sec peak 4 intensity
BRPI0820139A BRPI0820139B1 (en) 2007-12-12 2008-12-12 active antiperspirant composition, and process for obtaining an active antiperspirant composition
EP14155260.4A EP2740464B1 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
ZA2010/03774A ZA201003774B (en) 2007-12-12 2010-05-26 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
CO10074509A CO6290622A2 (en) 2007-12-12 2010-06-21 COMPOSITIONS OF ANTITRANSPIRANT ASSETS WITH A SEC CHROMATOGRAM PRESENTING A HIGH INTENSITY OF PICO 4 SEC TO REDUCE TRANSPIRATION
US13/565,370 US8562956B2 (en) 2007-12-12 2012-08-02 Method of making antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
ZA2012/06408A ZA201206408B (en) 2007-12-12 2012-08-24 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
US14/030,492 US8795641B2 (en) 2007-12-12 2013-09-18 Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
US14/306,182 US9427386B2 (en) 2007-12-12 2014-06-16 Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/087145 WO2009075678A1 (en) 2007-12-12 2007-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/086556 Continuation-In-Part WO2009076591A1 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
US12/446,045 Continuation-In-Part US8257689B2 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
US44604509A Continuation-In-Part 2007-12-12 2009-04-17

Publications (1)

Publication Number Publication Date
WO2009075678A1 true WO2009075678A1 (en) 2009-06-18

Family

ID=40329397

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/087145 Ceased WO2009075678A1 (en) 2007-12-12 2007-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
PCT/US2008/086556 Ceased WO2009076591A1 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2008/086556 Ceased WO2009076591A1 (en) 2007-12-12 2008-12-12 Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity

Country Status (14)

Country Link
US (3) US20100202993A1 (en)
EP (4) EP2740465A3 (en)
CN (4) CN101896156B (en)
AR (1) AR069657A1 (en)
AU (1) AU2008335029B2 (en)
BR (1) BRPI0820139B1 (en)
CA (2) CA2799270C (en)
CL (1) CL2008003684A1 (en)
CO (1) CO6290622A2 (en)
ES (1) ES2584256T3 (en)
MX (1) MX2010006370A (en)
RU (1) RU2440092C1 (en)
WO (2) WO2009075678A1 (en)
ZA (2) ZA201003774B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011016807A1 (en) 2009-08-06 2011-02-10 Colgate-Palmolive Company Method of making an antiperspirant active composition having sec chromatogram exhibiting high sec peak 4 intensity
WO2011153140A3 (en) * 2010-06-01 2012-04-19 Coty Inc. Antiperspirant compositions
WO2012060817A1 (en) * 2010-11-02 2012-05-10 Colgate-Palmolive Company Antiperspirant active compositions and manufacture thereof
US8257689B2 (en) 2007-12-12 2012-09-04 Colgate-Palmolive Company Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
US20130224140A1 (en) * 2010-11-02 2013-08-29 Colgate-Palmolive Company Aluminum Salt Containing High Percentage of Al30
US8562956B2 (en) 2007-12-12 2013-10-22 Colgate-Palmolive Company Method of making antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
WO2013158077A1 (en) 2012-04-17 2013-10-24 Colgate-Palmolive Company Method of making an aluminum salt composition
US9174851B2 (en) 2011-04-26 2015-11-03 Colgate-Palmolive Company Compositions containing polyhydroxyoxoaluminum cations and manufacture thereof
WO2016014011A1 (en) * 2014-07-21 2016-01-28 Colgate-Palmolive Company Antiperspirant compositions containing ethylenediamine disuccinate
WO2016066527A1 (en) 2014-10-27 2016-05-06 Unilever Plc Anhydrous antiperspirant compositions
US9408789B2 (en) 2011-04-26 2016-08-09 Colgate-Palmolive Company Antiperspirant active compositions and manufacture thereof
WO2017048983A1 (en) * 2015-09-18 2017-03-23 Colgate-Palmolive Company HIGH-pH ACTIVE COMPOSITIONS
WO2017076562A1 (en) 2015-11-06 2017-05-11 Unilever Plc Antiperspirant compositions
US9775791B2 (en) 2013-05-20 2017-10-03 Conopco, Inc. Method of manufacture of antiperspirant salts
US9867765B2 (en) 2014-11-19 2018-01-16 Conopco, Inc. Antiperspirant compositions
EP3295922A1 (en) 2013-05-20 2018-03-21 Unilever PLC Antiperspirant compositions
US10098821B2 (en) 2014-11-19 2018-10-16 Conopco, Inc. Process of manufacture of an antiperspirant composition
US10117814B2 (en) 2014-10-27 2018-11-06 Conopco, Inc. Anhydrous antiperspirant aerosol compositions
WO2019118432A1 (en) 2017-12-14 2019-06-20 Colgate-Palmolive Company Zirconium-based cluster as a dentin tubule occlusion agent
WO2019118351A1 (en) 2017-12-14 2019-06-20 Colgate-Palmolive Company Zirconium-based cluster as an antiperspirant and deodorant active
US10682293B2 (en) 2015-11-06 2020-06-16 Conopco, Inc. Aerosol antiperspirant product

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1219225A1 (en) * 2013-03-15 2017-03-31 Colgate-Palmolive Company Oral care compositions
CN105408256B (en) * 2013-07-31 2017-12-29 高露洁-棕榄公司 Show the chloride hydrate aluminium salt at high size exclusion chromatography peak 3
BR112016010562B1 (en) 2013-11-18 2019-12-31 Colgate Palmolive Co aqueous composition and use of disodium edta as a preservative in an antiperspirant composition
EP3185844B1 (en) * 2014-09-26 2020-09-16 Colgate-Palmolive Company Aluminum chlorohydrate salts exhibiting high sec peak 1
US10500145B2 (en) * 2015-06-19 2019-12-10 inkbox ink Inc. Body ink compositions and applicators
US9572758B2 (en) 2015-06-30 2017-02-21 Gulbrandsen Technologies, Inc. Method of making high performance activated aluminum sesquichlorohydrate powders
BR112018005766B1 (en) 2015-11-06 2021-07-13 Unilever Ip Holdings B.V. ANTI-TRANSPIRING PRODUCTS IN AEROSOL
EP3723706B1 (en) 2017-12-14 2023-11-22 Colgate-Palmolive Company Antiperspirant/deodorant compositions including biodegradable amino carboxylates and methods for the same
RU2704255C2 (en) * 2018-03-30 2019-10-25 Колгейт-Палмолив Компани Compositions for oral hygiene
JP7598932B2 (en) 2019-09-19 2024-12-12 ヘンケル・アクチェンゲゼルシャフト・ウント・コムパニー・コマンディットゲゼルシャフト・アウフ・アクチェン Photocurable (meth)acrylate composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074632A (en) * 1997-06-25 2000-06-13 The Gillette Company Polyhydric alcohol stabilized antiperspirant salt solutions
US20050265939A1 (en) * 2004-05-28 2005-12-01 Zijun Li High pH antiperspirant compositions of enhanced efficacy
WO2006091417A1 (en) * 2005-02-18 2006-08-31 Colgate-Palmolive Company Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine
US20070020211A1 (en) * 2005-07-22 2007-01-25 Reheis, Inc. Betaine with Calcium and/or Strontium Antiperspirants
US20070196303A1 (en) * 2006-02-17 2007-08-23 Reheis, Inc. Stable buffered aluminum compositions having high hplc bands iii and iv containing calcium/strontium

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979510A (en) 1973-11-23 1976-09-07 Armour Pharmaceutical Company Aluminum-zirconium anti-perspirant systems with complex aluminum buffers
US3991176A (en) 1973-11-23 1976-11-09 Armour Pharmaceutical Company Aluminum-zirconium anti-perspirant systems with hydroxy carboxylic compounds
US4359456A (en) 1976-01-14 1982-11-16 Lever Brothers Company Antiperspirant activity of basic aluminum compounds
GB2144992A (en) 1983-08-16 1985-03-20 Gillette Co Antiperspirants
US5358694A (en) * 1986-01-08 1994-10-25 Westwood Chemical Corporation Method for preparing basic aluminum halides and product produced therefrom
US4871525A (en) * 1986-10-24 1989-10-03 Westwood Chemical Corporation Antiperspirant composition and method of preparation
GB8619553D0 (en) * 1986-08-11 1986-09-24 Unilever Plc Antiperspirants
AU597822B2 (en) 1987-05-15 1990-06-07 Unilever Plc Transparent antiperspirant stick compositions
US5330751A (en) * 1988-04-14 1994-07-19 The Gilette Company Antiperspirant and method of making same
US5348720A (en) 1988-08-17 1994-09-20 The Mennen Company Basic aluminum antiperspirant active material having enhanced activity, antiperspirant active composition containing such material, and methods for preparation of such material and composition
CA2046170A1 (en) 1990-07-10 1992-01-11 Morton Lawrence Barr Basic aluminum antiperspirant active materials having enhanced activity, antiperspirant active compositions containing such materials, and methods for preparation of such materials and compositions
US5643558A (en) 1994-11-02 1997-07-01 The Gillette Company Method of making polyhydric alcohol solutions of enhanced efficacy antiperspirant actives
US5725846A (en) 1995-03-02 1998-03-10 The Gillette Company Clear antiperspirant stick containing dibenzylidene alditol and hydroxyalkyl cellulose
US5997850C1 (en) * 1997-10-29 2001-11-27 Colgate Palmolive Co Antiperspirant actives and formulations made therefrom
US6682749B1 (en) 1998-04-03 2004-01-27 Colgate-Palmolive Company Low Residue cosmetic composition
US6042816A (en) * 1998-08-19 2000-03-28 The Gillette Company Enhanced antiperspirant salts stabilized with calcium and concentrated aqueous solutions of such salts
US6136302A (en) * 1999-02-18 2000-10-24 The Procter & Gamble Company Process of making zirconium-aluminum antiperspirant active
US6149897A (en) * 1999-08-24 2000-11-21 The Procter & Gamble Company Process for making anhydrous compositions containing solubilized, enhanced antiperspirant active
ATE286707T1 (en) * 1999-10-01 2005-01-15 Unilever Nv ANTIPERSPIRANT COMPOSITION CONTAINING MICROEMULSIONS
AR031108A1 (en) * 2000-06-19 2003-09-10 Colgate Palmolive Co A METHOD FOR IMPROVING THE ACTIVITY OF AN ALUMINUM OR ALUMINUM / CIRCONIUM SALT CONTAINING SMALL AND LARGE ALUMINUM SPECIES, SALES SO OBTAINED AND ANTI-TRANSPIRING AND / OR DEODORANT PRODUCTS PREPARED WITH SUCH IMPROVED SALTS
US6375937B1 (en) * 2000-10-20 2002-04-23 Colgate-Palmolive Company Antiperspirant salts for enhanced cosmetic products
US6436381B1 (en) * 2000-10-25 2002-08-20 The Gillette Company Aluminum-zirconium antiperspirant salts with high peak 5 al content
GB0100549D0 (en) * 2001-01-09 2001-02-21 Unilever Plc Antiperspirant or deodorant compositions
US6342210B1 (en) * 2001-04-20 2002-01-29 Colgate-Palmolive Company Antiperspirant actives from a glass form and products made therewith
JP2005515423A (en) * 2002-01-10 2005-05-26 ケムルメイジ コーポレーション Method for detecting pathogenic microorganisms
US6726901B2 (en) * 2002-05-09 2004-04-27 The Gillette Company Stabilized antiperspirant compositions containing aluminum-zirconium salts with low M:Cl ratio
US6835373B2 (en) * 2002-07-12 2004-12-28 The Procter & Gamble Company Non-irritating antiperspirant compositions containing acidic antiperspirant active
WO2004012694A1 (en) * 2002-08-02 2004-02-12 The Gillette Company Clear personal care compositions containing visible capsules
US20040091436A1 (en) 2002-11-12 2004-05-13 Zijun Li Antiperspirant compositions of enhanced efficacy containing strontium
US6936242B2 (en) * 2002-11-15 2005-08-30 The Gillette Company Multi-portion antiperspirant composition
US20040198998A1 (en) 2003-04-04 2004-10-07 Marian Holerca Glycine-free antiperspirant salts with betaine for enhanced cosmetic products
US7105691B2 (en) * 2003-06-26 2006-09-12 Colgate-Palmolive Company Aluminum / zirconium / glycine antiperspirant actives stabilized with Betaine
US6942850B2 (en) 2003-08-15 2005-09-13 The Gillette Company Aqueous alcoholic antiperspirant composition containing calcium enhanced antiperspirant salt
US6902724B1 (en) * 2004-03-24 2005-06-07 Reheis, Inc. Enhanced efficacy basic aluminum halides, antiperspirant active compositions and methods for making
US8883129B2 (en) * 2005-01-13 2014-11-11 The Procter & Gamble Company Enhanced efficacy antiperspirant active
ES2323980T3 (en) 2005-03-31 2009-07-28 Unilever N.V. PROCEDURE TO PREPARE ALUMINUM SPECIES.
US20060292098A1 (en) * 2005-05-19 2006-12-28 Scavone Timothy A Consumer noticeable improvement in wetness protection
US20070003499A1 (en) * 2005-06-30 2007-01-04 The Gillette Company Particulate enhanced efficacy antiperspirant salt with raised pH
CL2006003116A1 (en) * 2005-11-16 2008-02-29 Colgate Palmolive Co ANTI-TRANSPIRING COMPOSITION THAT INCLUDES AT LEAST ONE CHOSEN ALUMINUM SALT, ZIRCONY ALUMINUM, A COMPLEX ALUMINUM SALT OR A COMPLEX ALUMINUM-ZIRCONY SALT, A HYDROXIACIDE AND AN ACID COMPOUND OF QUATERNARY AMMONIUM; PROCESS TO PREPARE
US8801909B2 (en) * 2006-01-06 2014-08-12 Nextchem, Llc Polymetal hydroxychloride processes and compositions: enhanced efficacy antiperspirant salt compositions
WO2009075678A1 (en) 2007-12-12 2009-06-18 Colgate-Palmolive Company Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074632A (en) * 1997-06-25 2000-06-13 The Gillette Company Polyhydric alcohol stabilized antiperspirant salt solutions
US20050265939A1 (en) * 2004-05-28 2005-12-01 Zijun Li High pH antiperspirant compositions of enhanced efficacy
WO2006091417A1 (en) * 2005-02-18 2006-08-31 Colgate-Palmolive Company Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine
US20070020211A1 (en) * 2005-07-22 2007-01-25 Reheis, Inc. Betaine with Calcium and/or Strontium Antiperspirants
US20070196303A1 (en) * 2006-02-17 2007-08-23 Reheis, Inc. Stable buffered aluminum compositions having high hplc bands iii and iv containing calcium/strontium

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562956B2 (en) 2007-12-12 2013-10-22 Colgate-Palmolive Company Method of making antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
US8795641B2 (en) 2007-12-12 2014-08-05 Colgate-Palmolive Company Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
US8257689B2 (en) 2007-12-12 2012-09-04 Colgate-Palmolive Company Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
US9427386B2 (en) 2007-12-12 2016-08-30 Colgate-Palmolive Company Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
WO2011016807A1 (en) 2009-08-06 2011-02-10 Colgate-Palmolive Company Method of making an antiperspirant active composition having sec chromatogram exhibiting high sec peak 4 intensity
US8147810B2 (en) * 2009-08-06 2012-04-03 Colgate-Palmolive Company Method of making an antiperspirant active composition having SEC chromatogram exhibiting high SEC peak 4 intensity
WO2011153140A3 (en) * 2010-06-01 2012-04-19 Coty Inc. Antiperspirant compositions
CN102946846A (en) * 2010-06-01 2013-02-27 科蒂公司 Antiperspirant composition
US9144695B2 (en) 2010-06-01 2015-09-29 Coty Inc. Antiperspirant compositions
AU2010363348B2 (en) * 2010-11-02 2014-07-31 Colgate-Palmolive Company Antiperspirant active compositions and manufacture thereof
WO2012060817A1 (en) * 2010-11-02 2012-05-10 Colgate-Palmolive Company Antiperspirant active compositions and manufacture thereof
US9539188B2 (en) 2010-11-02 2017-01-10 Colgate-Palmolive Company Antiperspirant active compositions and manufacture thereof
US20130224140A1 (en) * 2010-11-02 2013-08-29 Colgate-Palmolive Company Aluminum Salt Containing High Percentage of Al30
US10118832B2 (en) 2010-11-02 2018-11-06 Colgate-Palmolive Company Aluminum salt containing high percentage of Al30
WO2012061280A3 (en) * 2010-11-02 2013-05-23 Colgate-Palmolive Company Aluminum salt containing high percentage of al30
US9463985B2 (en) 2010-11-02 2016-10-11 Colgate-Palmolive Company Aluminum salt containing high percentage of Al30
US9174851B2 (en) 2011-04-26 2015-11-03 Colgate-Palmolive Company Compositions containing polyhydroxyoxoaluminum cations and manufacture thereof
US9717663B2 (en) 2011-04-26 2017-08-01 Colgate-Palmolive Company Antiperspirant active compositions and manufacture thereof
US9408789B2 (en) 2011-04-26 2016-08-09 Colgate-Palmolive Company Antiperspirant active compositions and manufacture thereof
WO2013158077A1 (en) 2012-04-17 2013-10-24 Colgate-Palmolive Company Method of making an aluminum salt composition
EP2838847B1 (en) 2012-04-17 2016-11-16 Colgate-Palmolive Company Method of making an aluminum salt composition
US9775791B2 (en) 2013-05-20 2017-10-03 Conopco, Inc. Method of manufacture of antiperspirant salts
EP3295922A1 (en) 2013-05-20 2018-03-21 Unilever PLC Antiperspirant compositions
US10111817B2 (en) 2014-07-21 2018-10-30 Colgate-Palmolive Company Antiperspirant compositions containing ethylenediamine disuccinate
WO2016014011A1 (en) * 2014-07-21 2016-01-28 Colgate-Palmolive Company Antiperspirant compositions containing ethylenediamine disuccinate
US10398633B2 (en) 2014-10-27 2019-09-03 Conopco, Inc. Anhydrous antiperspirant compositions
US10117814B2 (en) 2014-10-27 2018-11-06 Conopco, Inc. Anhydrous antiperspirant aerosol compositions
WO2016066527A1 (en) 2014-10-27 2016-05-06 Unilever Plc Anhydrous antiperspirant compositions
US10729627B2 (en) 2014-10-27 2020-08-04 Conopco, Inc. Anhydrous antiperspirant compositions
US10098821B2 (en) 2014-11-19 2018-10-16 Conopco, Inc. Process of manufacture of an antiperspirant composition
US9867765B2 (en) 2014-11-19 2018-01-16 Conopco, Inc. Antiperspirant compositions
WO2017048983A1 (en) * 2015-09-18 2017-03-23 Colgate-Palmolive Company HIGH-pH ACTIVE COMPOSITIONS
WO2017076562A1 (en) 2015-11-06 2017-05-11 Unilever Plc Antiperspirant compositions
US10632052B2 (en) 2015-11-06 2020-04-28 Conopco, Inc. Antiperspirant compositions
US10682293B2 (en) 2015-11-06 2020-06-16 Conopco, Inc. Aerosol antiperspirant product
WO2019118432A1 (en) 2017-12-14 2019-06-20 Colgate-Palmolive Company Zirconium-based cluster as a dentin tubule occlusion agent
WO2019118351A1 (en) 2017-12-14 2019-06-20 Colgate-Palmolive Company Zirconium-based cluster as an antiperspirant and deodorant active
US11918667B2 (en) 2017-12-14 2024-03-05 Colgate-Palmolive Company Zirconium-based cluster as an antiperspirant and deodorant active

Also Published As

Publication number Publication date
RU2440092C1 (en) 2012-01-20
CN103690384A (en) 2014-04-02
ES2584256T3 (en) 2016-09-26
CL2008003684A1 (en) 2010-06-04
CN102920610B (en) 2016-01-13
WO2009076591A1 (en) 2009-06-18
AU2008335029B2 (en) 2012-02-02
CA2706142C (en) 2013-10-01
MX2010006370A (en) 2010-06-30
CN103083195B9 (en) 2018-03-30
AR069657A1 (en) 2010-02-10
CA2799270A1 (en) 2009-06-18
BRPI0820139A2 (en) 2014-09-30
US9427386B2 (en) 2016-08-30
US8562956B2 (en) 2013-10-22
CN101896156A (en) 2010-11-24
CA2799270C (en) 2013-10-08
EP2740465A2 (en) 2014-06-11
EP2229136B1 (en) 2016-04-27
EP2810638A1 (en) 2014-12-10
CN102920610A (en) 2013-02-13
AU2008335029A1 (en) 2009-06-18
EP2229136A1 (en) 2010-09-22
US20100202993A1 (en) 2010-08-12
US20130022566A1 (en) 2013-01-24
EP2740465A3 (en) 2014-12-17
EP2740464A2 (en) 2014-06-11
BRPI0820139B1 (en) 2017-04-11
CA2706142A1 (en) 2009-06-18
CN103083195A (en) 2013-05-08
CO6290622A2 (en) 2011-06-20
EP2740464A3 (en) 2014-12-17
ZA201206408B (en) 2013-03-27
CN103690384B (en) 2016-03-30
ZA201003774B (en) 2012-11-28
CN103083195B (en) 2018-02-13
EP2810638B1 (en) 2018-03-07
CN101896156B (en) 2017-09-19
US20150132241A1 (en) 2015-05-14
EP2740464B1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
WO2009075678A1 (en) Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity
US8795641B2 (en) Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity
US9539188B2 (en) Antiperspirant active compositions and manufacture thereof
US20040265255A1 (en) Aluminum / zirconium / glycine antiperspirant actives stabilized with betaine
AU2012207017B2 (en) Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11917863

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07855078

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07855078

Country of ref document: EP

Kind code of ref document: A1